Cyclosporine vs Tacrolimus — Cost, Coverage & Plan Comparison

Pick the drugs you want to compare.

Up to 4 drugsCross-class or same-class

Start with the molecules your plan spends the most on. Most useful comparisons live within the same therapeutic class — switching across classes requires deeper clinical review.

Drug 1

Drug 2

Drug 3 (optional)

Drug 4 (optional)

Side by side, line by line.

Federal data onlyNo PBM pricing assumed

Compare across

11 dimensions

Calcineurin Inhibitor Immunosuppressant

Cyclosporine

Brand: CEQUA

First FDA approval: 1983-11-14

Calcineurin Inhibitor Immunosuppressant

Tacrolimus

Brand: Envarsus

First FDA approval: 1994-04-08

Lowest NADACAcquisition cost floor across all NDCs

$0.310Per unit

$0.154Per unit

Average NADACAcross all dosage forms and strengths

$5.30Up to $112.33

$0.687Up to $7.35

Generic manufacturersActive ANDA holders — FDA Orange Book

1528 total ANDAs filed

1544 total ANDAs filed

Annualized Part D spendCY2024 — CMS Part D Spending Dashboard

$2.51BFull year

$156.6MFull year

Part D claims (CY24)Total fills, all strengths

3.5M1.4M beneficiaries

1.0M464K beneficiaries

Avg cost per claimCalculated: total spend ÷ total claims

$718Per claim, all NDCs

$150Per claim, all NDCs

Part D plans surveyed2026 plan year — CMS Formulary file

329Across CMS plan year

Prior-authorization frictionPlan-NDC pairs requiring PA

2589Substantial friction

2555Substantial friction

Step therapy appliedPlan-NDC pairs requiring step therapy

0None

48Limited friction

FDA shortage statusLive cross-reference vs FDA Drug Shortage Database

NoneClear

Generic availableFDA Orange Book

Yes15 manufacturers